Key facts
- It has raised $3.5M; the latest was Later Stage VC in Apr 2026.
- Notable investors include CDP Venture Capital (Rome), Panakes Partners, ENEA Tech Biomedical.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Aileens Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Aileens Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aileens Pharma
Developer of non-steroidal drugs designed for the treatment of atopic dermatitis and other skin diseases. The company's treatments challenge the lack of non-pharmacological therapies and focus on creating medicines for atopic dermatitis, seborrheic dermatitis, and psoriasis, enabling doctors and healthcare organizations to take protective measures and treat the symptoms related to skin diseases.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2018
- Employees
- 4
- Website
- aileenspharma.com/
- Ownership
- Privately Held (backing)
Aileens Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aileens Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aileens Pharma in its N-PORT filings yet. We sweep new filings monthly.